Adlai Nortye Ltd. Sponsored ADR (ANL) vs 4D Molecular Therapeutics, Inc. (FDMT)

Adlai Nortye Ltd. Sponsored ADR and 4D Molecular Therapeutics, Inc. are both Biotechnology companies. Adlai Nortye Ltd. Sponsored ADR and 4D Molecular Therapeutics, Inc. are of similar size ($711.0M and $710.1M). Across the 9 metrics below, Adlai Nortye Ltd. Sponsored ADR leads on 8 and 4D Molecular Therapeutics, Inc. on 1.

Valuation

Metric ANL FDMT Biotechnology median
P/E — n/m 8.50
P/S — 9.27 9.71
P/B n/m 2.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 5.56 9.21
Earnings yield — (21.66%) (33.15%)
Free cash flow yield 0.00% (18.28%) (25.50%)

Profitability

Metric ANL FDMT Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin — (214.24%) 0.00%
Net margin — (194.74%) 0.00%
Free cash flow margin 0.00% (169.51%) 0.00%
Return on equity 0.00% (43.25%) (56.36%)
Return on assets 0.00% (37.09%) (48.04%)
Return on invested capital 0.00% (186.91%) 0.00%

Growth

Metric ANL FDMT Biotechnology median
Revenue growth (TTM) — 278,712.12% 6.02%
EPS growth (last fiscal year) 31.48% 18.79% 30.26%
Revenue growth, 5-year CAGR — 44.32% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ANL FDMT Biotechnology median
Debt to equity 0.12 0.05 0.00
Current ratio 9.55 8.03 4.72
Net debt to EBITDA (0.05) 2.52 0.96

Dividend

Metric ANL FDMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ANL FDMT Biotechnology median
Market cap 710.05m 710.99m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack